U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H14N4O5S
Molecular Weight 398.393
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of SULFASALAZINE

SMILES

OC(=O)C1=C(O)C=CC(=C1)\N=N\C2=CC=C(C=C2)S(=O)(=O)NC3=CC=CC=N3

InChI

InChIKey=NCEXYHBECQHGNR-QZQOTICOSA-N
InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+

HIDE SMILES / InChI

Molecular Formula C18H14N4O5S
Molecular Weight 398.393
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/007073s124lbl.pdf

Sulfasalazine is an anti-inflammatory indicated for the treatment of ulcerative colitis and rheumatoid arthritis. The mode of action of Sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and in vitromodels, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of Sulfasalazine, SP and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown. Sulfasalazine is used for the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent. Sulfasalazine is marketed under the trade name Azulfidine among others.

CNS Activity

Curator's Comment: sulfasalazine can effectively penetrate the blood-brain barrier (BBB)

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AZULFIDINE

Approved Use

AZULFIDINE EN-tabs Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; b) for the prolongation of the remission period between acute attacks of ulcerative colitis; c) in the treatment of patients with rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs); and in the treatment of pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal antiinflammatory drugs.

Launch Date

1950
Primary
AZULFIDINE

Approved Use

AZULFIDINE EN-tabs Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; b) for the prolongation of the remission period between acute attacks of ulcerative colitis; c) in the treatment of patients with rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs); and in the treatment of pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal antiinflammatory drugs.

Launch Date

1950
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12.9 μg/mL
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFASALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
98 μg × h/mL
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFASALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
27.4 μM × h
6.5 mmol single, rectal
dose: 6.5 mmol
route of administration: Rectal
experiment type: SINGLE
co-administered:
SULFASALAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.6 h
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFASALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7.6 h
unknown, intravenous
SULFASALAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
25 g single, oral
Overdose
Dose: 25 g
Route: oral
Route: single
Dose: 25 g
Sources: Page: p.544
unhealthy, 23
n = 1
Health Status: unhealthy
Condition: Crohn’s colitis | Major depression
Age Group: 23
Sex: M
Population Size: 1
Sources: Page: p.544
Disc. AE: Headache, Dizziness...
AEs leading to
discontinuation/dose reduction:
Headache
Dizziness
Sources: Page: p.544
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Co-administed with::
paracetamol, p.o(50 g, single)
Sources: Page: p.240
unhealthy, 26
n = 1
Health Status: unhealthy
Condition: Ankylosing spondylitis
Age Group: 26
Sex: M
Population Size: 1
Sources: Page: p.240
Disc. AE: Lactic acidosis, Seizures...
AEs leading to
discontinuation/dose reduction:
Lactic acidosis (severe)
Seizures
Coagulopathy
Hyperglycemia
Ketosis
Methemoglobinemia
Sources: Page: p.240
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources: Page: p.72
unhealthy, 43
n = 24
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 43
Sex: M+F
Population Size: 24
Sources: Page: p.72
Disc. AE: Headache, Headache...
AEs leading to
discontinuation/dose reduction:
Headache (severe, 16.7%)
Headache (8.3%)
Nausea (12.5%)
Nausea (severe, 8.3%)
Acute pancreatitis (4.2%)
Abdominal pain (4.2%)
Lethargy (4.2%)
Depression (8.3%)
Dizziness (severe, 4.2%)
Rash (4.2%)
Light headedness (4.2%)
Sources: Page: p.72
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources: Page: p.813, 814
unhealthy, 8.4 ±4.4
n = 35
Health Status: unhealthy
Condition: Juvenile chronic arthritis
Age Group: 8.4 ±4.4
Sex: M+F
Population Size: 35
Sources: Page: p.813, 814
Disc. AE: Toxic reaction (NOS), Anorexia...
AEs leading to
discontinuation/dose reduction:
Toxic reaction (NOS) (serious, 2.9%)
Anorexia (serious, 2.9%)
Nausea (serious, 2.9%)
Abdominal discomfort (serious, 2.9%)
Headache (serious, 2.9%)
Fever (serious, 2.9%)
Rash (serious, 2.9%)
Lymphadenopathy cervical (serious, 2.9%)
Leukopenia (5.7%)
Sources: Page: p.813, 814
AEs

AEs

AESignificanceDosePopulation
Dizziness Disc. AE
25 g single, oral
Overdose
Dose: 25 g
Route: oral
Route: single
Dose: 25 g
Sources: Page: p.544
unhealthy, 23
n = 1
Health Status: unhealthy
Condition: Crohn’s colitis | Major depression
Age Group: 23
Sex: M
Population Size: 1
Sources: Page: p.544
Headache Disc. AE
25 g single, oral
Overdose
Dose: 25 g
Route: oral
Route: single
Dose: 25 g
Sources: Page: p.544
unhealthy, 23
n = 1
Health Status: unhealthy
Condition: Crohn’s colitis | Major depression
Age Group: 23
Sex: M
Population Size: 1
Sources: Page: p.544
Coagulopathy Disc. AE
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Co-administed with::
paracetamol, p.o(50 g, single)
Sources: Page: p.240
unhealthy, 26
n = 1
Health Status: unhealthy
Condition: Ankylosing spondylitis
Age Group: 26
Sex: M
Population Size: 1
Sources: Page: p.240
Hyperglycemia Disc. AE
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Co-administed with::
paracetamol, p.o(50 g, single)
Sources: Page: p.240
unhealthy, 26
n = 1
Health Status: unhealthy
Condition: Ankylosing spondylitis
Age Group: 26
Sex: M
Population Size: 1
Sources: Page: p.240
Ketosis Disc. AE
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Co-administed with::
paracetamol, p.o(50 g, single)
Sources: Page: p.240
unhealthy, 26
n = 1
Health Status: unhealthy
Condition: Ankylosing spondylitis
Age Group: 26
Sex: M
Population Size: 1
Sources: Page: p.240
Methemoglobinemia Disc. AE
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Co-administed with::
paracetamol, p.o(50 g, single)
Sources: Page: p.240
unhealthy, 26
n = 1
Health Status: unhealthy
Condition: Ankylosing spondylitis
Age Group: 26
Sex: M
Population Size: 1
Sources: Page: p.240
Seizures Disc. AE
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Co-administed with::
paracetamol, p.o(50 g, single)
Sources: Page: p.240
unhealthy, 26
n = 1
Health Status: unhealthy
Condition: Ankylosing spondylitis
Age Group: 26
Sex: M
Population Size: 1
Sources: Page: p.240
Lactic acidosis severe
Disc. AE
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Co-administed with::
paracetamol, p.o(50 g, single)
Sources: Page: p.240
unhealthy, 26
n = 1
Health Status: unhealthy
Condition: Ankylosing spondylitis
Age Group: 26
Sex: M
Population Size: 1
Sources: Page: p.240
Nausea 12.5%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources: Page: p.72
unhealthy, 43
n = 24
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 43
Sex: M+F
Population Size: 24
Sources: Page: p.72
Abdominal pain 4.2%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources: Page: p.72
unhealthy, 43
n = 24
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 43
Sex: M+F
Population Size: 24
Sources: Page: p.72
Acute pancreatitis 4.2%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources: Page: p.72
unhealthy, 43
n = 24
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 43
Sex: M+F
Population Size: 24
Sources: Page: p.72
Lethargy 4.2%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources: Page: p.72
unhealthy, 43
n = 24
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 43
Sex: M+F
Population Size: 24
Sources: Page: p.72
Light headedness 4.2%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources: Page: p.72
unhealthy, 43
n = 24
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 43
Sex: M+F
Population Size: 24
Sources: Page: p.72
Rash 4.2%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources: Page: p.72
unhealthy, 43
n = 24
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 43
Sex: M+F
Population Size: 24
Sources: Page: p.72
Depression 8.3%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources: Page: p.72
unhealthy, 43
n = 24
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 43
Sex: M+F
Population Size: 24
Sources: Page: p.72
Headache 8.3%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources: Page: p.72
unhealthy, 43
n = 24
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 43
Sex: M+F
Population Size: 24
Sources: Page: p.72
Headache severe, 16.7%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources: Page: p.72
unhealthy, 43
n = 24
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 43
Sex: M+F
Population Size: 24
Sources: Page: p.72
Dizziness severe, 4.2%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources: Page: p.72
unhealthy, 43
n = 24
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 43
Sex: M+F
Population Size: 24
Sources: Page: p.72
Nausea severe, 8.3%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources: Page: p.72
unhealthy, 43
n = 24
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 43
Sex: M+F
Population Size: 24
Sources: Page: p.72
Leukopenia 5.7%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources: Page: p.813, 814
unhealthy, 8.4 ±4.4
n = 35
Health Status: unhealthy
Condition: Juvenile chronic arthritis
Age Group: 8.4 ±4.4
Sex: M+F
Population Size: 35
Sources: Page: p.813, 814
Abdominal discomfort serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources: Page: p.813, 814
unhealthy, 8.4 ±4.4
n = 35
Health Status: unhealthy
Condition: Juvenile chronic arthritis
Age Group: 8.4 ±4.4
Sex: M+F
Population Size: 35
Sources: Page: p.813, 814
Anorexia serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources: Page: p.813, 814
unhealthy, 8.4 ±4.4
n = 35
Health Status: unhealthy
Condition: Juvenile chronic arthritis
Age Group: 8.4 ±4.4
Sex: M+F
Population Size: 35
Sources: Page: p.813, 814
Fever serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources: Page: p.813, 814
unhealthy, 8.4 ±4.4
n = 35
Health Status: unhealthy
Condition: Juvenile chronic arthritis
Age Group: 8.4 ±4.4
Sex: M+F
Population Size: 35
Sources: Page: p.813, 814
Headache serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources: Page: p.813, 814
unhealthy, 8.4 ±4.4
n = 35
Health Status: unhealthy
Condition: Juvenile chronic arthritis
Age Group: 8.4 ±4.4
Sex: M+F
Population Size: 35
Sources: Page: p.813, 814
Lymphadenopathy cervical serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources: Page: p.813, 814
unhealthy, 8.4 ±4.4
n = 35
Health Status: unhealthy
Condition: Juvenile chronic arthritis
Age Group: 8.4 ±4.4
Sex: M+F
Population Size: 35
Sources: Page: p.813, 814
Nausea serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources: Page: p.813, 814
unhealthy, 8.4 ±4.4
n = 35
Health Status: unhealthy
Condition: Juvenile chronic arthritis
Age Group: 8.4 ±4.4
Sex: M+F
Population Size: 35
Sources: Page: p.813, 814
Rash serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources: Page: p.813, 814
unhealthy, 8.4 ±4.4
n = 35
Health Status: unhealthy
Condition: Juvenile chronic arthritis
Age Group: 8.4 ±4.4
Sex: M+F
Population Size: 35
Sources: Page: p.813, 814
Toxic reaction (NOS) serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources: Page: p.813, 814
unhealthy, 8.4 ±4.4
n = 35
Health Status: unhealthy
Condition: Juvenile chronic arthritis
Age Group: 8.4 ±4.4
Sex: M+F
Population Size: 35
Sources: Page: p.813, 814
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.
1996 Dec
Patents

Sample Use Guides

Initial Therapy : Adults: 3 to 4 g daily in evenly divided doses with dosage intervals not exceeding eight hours. In some cases, it is advisable to initiate therapy with a smaller dosage, e.g., 1 to 2 g daily, to reduce possible gastrointestinal intolerance. If daily doses exceeding 4 g are required to achieve desired effects, the increased risk of toxicity should be kept in mind. Children, six years of age and older: 40 to 60 mg/kg body weight in each 24-hour period, divided into 3 to 6 doses. Maintenance Therapy : Adults: 2 g daily. Children, six years of age and older: 30 mg/kg body weight in each 24-hour period, divided into 4 doses.
Route of Administration: Oral
In Vitro Use Guide
Inhibition of arachidonate 5-lipoxygenase by sulfasalazine and its major metabolites was observed at higher concentrations (2-3 mM).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:46:47 GMT 2023
Edited
by admin
on Fri Dec 15 15:46:47 GMT 2023
Record UNII
3XC8GUZ6CB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFASALAZINE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
SULFASALAZINE [USAN]
Common Name English
sulfasalazine [INN]
Common Name English
SULFASALAZINE [ORANGE BOOK]
Common Name English
SALAZOSULFAPYRIDINE [JAN]
Common Name English
SALAZOPYRIN
Brand Name English
SULFASALAZINE [EP MONOGRAPH]
Common Name English
SULFASALAZINE [MART.]
Common Name English
SULFASALAZINE [MI]
Common Name English
SULFASALAZINE [USP-RS]
Common Name English
SULFASALAZINE [VANDF]
Common Name English
SULFASALAZINUM [WHO-IP LATIN]
Common Name English
AZULFIDINE
Brand Name English
SALICYLAZOSULFAPYRIDINE
Common Name English
NSC-203730
Code English
NSC-667219
Code English
Sulfasalazine [WHO-DD]
Common Name English
SULFASALAZINE [USP MONOGRAPH]
Common Name English
BENZOSULFA
Common Name English
SULFASALAZINE [IARC]
Common Name English
SULFASALAZOPYRIDINE
Common Name English
SULFASALAZINE [WHO-IP]
Common Name English
2-HYDROXY-5-((4-((2-PYRIDINYLAMINO)SULFONYL)PHENYL)AZO)BENZOIC ACID [WHO-IP]
Common Name English
BENZOIC ACID, 2-HYDROXY-5-(2-(4-((2-PYRIDINYLAMINO)SULFONYL)PHENYL)DIAZENYL)-
Systematic Name English
SULFASALAZINE [HSDB]
Common Name English
SULPHASALAZINE
Common Name English
Classification Tree Code System Code
NDF-RT N0000005760
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
NDF-RT N0000005760
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
WHO-VATC QA07EC01
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
NCI_THESAURUS C257
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
LIVERTOX NBK548792
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
NDF-RT N0000005760
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
NDF-RT N0000175781
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 2.4
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
WHO-ATC A07EC01
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 17.3
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
NDF-RT N0000005760
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
Code System Code Type Description
MESH
D012460
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
EPA CompTox
DTXSID0021256
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
FDA UNII
3XC8GUZ6CB
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
NCI_THESAURUS
C29469
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
INN
2210
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
CAS
599-79-1
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
DRUG CENTRAL
2525
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
DAILYMED
3XC8GUZ6CB
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
NSC
203730
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
RS_ITEM_NUM
1636005
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
EVMPD
SUB20720
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
RXCUI
9524
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY RxNorm
NSC
667219
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
EVMPD
SUB10727MIG
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
SMS_ID
100000091572
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
SULFASALAZINE
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY Description: A bright yellow to brownish yellow powder; odourless. Solubility: Practically insoluble in water and ether R; very slightly soluble in ethanol (~750 g/l) TS; soluble in alkali hydroxides. Category: Antibacterial drug. Storage: Sulfasalazine should be kept in a tightly closed container, protected from light. Additional information: Sulfasalazine melts at about 255?C with decomposition. Definition: Sulfasalazine contains not less than 93.0% and not more than 103.0% of C18H14N4O5S, calculated with reference to the dried substance.
DRUG BANK
DB00795
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
HSDB
3395
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
ECHA (EC/EINECS)
209-974-3
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
MERCK INDEX
m10343
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL421
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
IUPHAR
4840
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
WIKIPEDIA
Sulfasalazine
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
CHEBI
9334
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
LACTMED
Sulfasalazine
Created by admin on Fri Dec 15 15:46:48 GMT 2023 , Edited by admin on Fri Dec 15 15:46:48 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Prevents translocation into nuclease
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE ACTIVE -> PARENT
Inhibite the Hb-catalyzed peroxidative reaction
METABOLITE INACTIVE -> PARENT
Not inhibite the Hb-catalyzed peroxidative reaction
METABOLITE -> PARENT
METABOLITE LESS ACTIVE -> PARENT
Inhibite the Hb-catalyzed peroxidative reaction
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC